Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Pancreatic Cancer: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Pancreatic Cancer

Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Non-Small Cell Lung Cancer

Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Triple-Negative Breast Cancer (TNBC)

Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Ovarian Cancer: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Ovarian Cancer

Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Colorectal Cancer: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Colorectal Cancer

Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Kidney Cancer (Renal Cell Cancer)

Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Gastric Cancer: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Gastric Cancer

Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Solid Tumor: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Solid Tumor

Data Insights

P-MUC1C-ALLO1 by Poseida Therapeutics for Esophageal Cancer: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Esophageal Cancer